Lindbrook Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Lindbrook Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$199	–	2975
2022 Q4	$199	Sell	6 -6	-50%	-$193	﹤0.01%	2727
2022 Q3	$0	Buy	+12	New	+$389	﹤0.01%	3003
2022 Q1	–	Sell	-124	Closed	-$3K	–	2662
2021 Q4	$3K	Hold	124	–	–	﹤0.01%	1727
2021 Q3	$2K	Sell	124 -32	-21%	-$638	﹤0.01%	1652
2021 Q2	$3K	Hold	156	–	–	﹤0.01%	1533
2021 Q1	$4K	Hold	156	–	–	﹤0.01%	1372
2020 Q4	$3K	Buy	156 +32	+26%	+$598	﹤0.01%	1397
2020 Q3	$2K	Hold	124	–	–	﹤0.01%	1472
2020 Q2	$3K	Hold	124	–	–	﹤0.01%	1326
2020 Q1	$1K	Buy	+124	New	+$1.04K	﹤0.01%	1627
2019 Q3	–	Sell	-110	Closed	-$1K	–	1562
2019 Q2	$1K	Hold	110	–	–	﹤0.01%	1372
2019 Q1	$1K	Hold	110	–	–	﹤0.01%	1359
2018 Q4	$1K	Buy	+110	New	+$1.88K	﹤0.01%	1315

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lindbrook Capital's VIVO Position: Q1 2023 in Review

Lindbrook Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 6 shares — an estimated $199 sold.

Lindbrook Capital first reported a position in VIVO in Q4 2018 and held it in 13 quarters. The position peaked at $4K in Q1 2021. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Lindbrook Capital reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Lindbrook Capital sold 6 Meridian Bioscience Inc shares in Q1 2023, an estimated $199.
Lindbrook Capital first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 13 quarters.
Lindbrook Capital's Meridian Bioscience Inc position peaked at $4K in Q1 2021.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Lindbrook Capital's 13F filing for Q1 2023, filed 26 Apr 2023.